CStone Pharmaceuticals (2616) H2 2024 earnings summary

Executive summary

• Achieved first-time profitability in 2024H1, with total FY2024 revenue of RMB 407.2 million, driven by license fee income and global partnerships, despite a 12.2% year-over-year decline.

• Net loss for the year narrowed by up to 75.2% to RMB 91.2 million, reflecting stringent cost control and business model transition.

• Advanced global strategy for sugemalimab, securing EU & UK approvals and expanding commercial partnerships across 40 countries.

• Robust R&D pipeline with multiple first-in-class and best-in-class assets in oncology and autoimmune diseases, including CS5001 and CS2009.

• Major cost reductions achieved in R&D, administrative, and selling expenses, driven by lower milestone fees and employee costs.

Financial highlights

• FY2024 revenue: RMB 407.2 million (down 12% year-over-year); license fee income up 113% to RMB 204.0 million.

• Net loss narrowed by up to 75.2% year-over-year to RMB 91.2 million; adjusted loss (excluding share-based payments) was RMB 94.0 million.

• Operating expenses reduced by 60% to RMB 349.1 million; R&D expenses down to RMB 124.7–134.7 million.

• Cash and time deposits at year-end: RMB 672.9 million, with reduced operating cash burn.

• Gross profit margin was 59.0% in 2024.

Outlook and guidance

• Anticipates further global expansion of sugemalimab and additional ex-China partnerships in 2025.

• Focus on advancing CS5001 and CS2009 towards pivotal trials and global partnerships.

• Multiple near-term catalysts expected, including clinical data disclosures and IND filings for key pipeline assets.

• Plans to maximize commercial value of approved products through strategic collaborations and manufacturing localization.

• Continued investment in proprietary technology platforms and early-stage pipeline candidates.